Stockreport

Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) [Yahoo! Finance]

HONG KONG EX&CL UNSP/ADR  (HKXCY) 
NASDAQ:AMEX Investor Relations: hkexgroup.com/investor-relations?sc_lang=en
PDF Ascentage Pharma to receive an option payment of 100 million USD upon closing and be eligible for an option exercise fee and additional potential milestones of up to ap [Read more]